Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection

Robert J. LoCasale¹ · Chris L. Pashos² · Ben Gutierrez³ · Nancy A. Dreyer⁴ · Toby Collins⁵ · Alan Calleja⁵ · Michael J. Seewald⁶ · Jonathan M. Plumb⁷ · Johan Liwing⁸ · Maurille Feudjo Tepie⁹ · Sajan Khosla¹⁰

Published online: 30 October 2020
© The Author(s) 2020

Correction to: Therapeutic Innovation & Regulatory Science
<https://doi.org/10.1007/s43441-020-00193-5>

The article Bridging the Gap Between RCTs and RWE Through Endpoint Selection, written by Robert J. LoCasale, Chris L. Pashos, Ben Gutierrez, Nancy A. Dreyer, Toby Collins, Alan Calleja, Michael J. Seewald, Jonathan M. Plumb, Johan Liwing, Maurille Feudjo Tepie, and Sajan Khosla, was originally published electronically on the publisher's internet portal on 06 July 2020 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on 01 September 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s43441-020-00193-5>.

✉ Sajan Khosla
sajan.khosla@astrazeneca.com

¹ Real World Evidence, Sanofi, Bridgewater, NJ, USA

² AbbVie, Chicago, IL, USA

³ GSK, Philadelphia, PA, USA

⁴ IQVIA, Real-World Solutions, Cambridge, MA, USA

⁵ IQVIA, Real-World Solutions, London, UK

⁶ Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland

⁷ Ferring Pharmaceuticals SA, St Prex, Switzerland

⁸ CellProtect Nordic Pharmaceuticals, Stockholm, Sweden

⁹ Center for Observational Research, Amgen, Cambridge, UK

¹⁰ Real-World Evidence, Oncology R&D, AstraZeneca, Cambridge, UK